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Background: In Evidence-Based Medicine, clinical practice guidelines and systematic reviews are crucial devices for
medical practitioners in making clinical decision. Clinical practice guidelines are systematically developed
statements to support health care decisions for specific circumstances whereas systematic reviews are summaries of
evidence on clearly formulated clinical questions. Biomarkers are biological measurements (primarily molecular) that
are used to diagnose, predict treatment outcomes and prognosticate disease and are increasingly used in
randomized controlled trials (RCT).
Methods: We search PubMed for systematic reviews, RCTs, case reports and non-systematic reviews with and
without mentions of biomarkers between years 1990–2011. We compared the frequency and growth rate of
biomarkers and non-biomarkers publications. We also compared the growth of the proportion of biomarker-based
RCTs with the growth of the proportion of biomarker-based systematic reviews.
Results: With 147,774 systematic reviews indexed in PubMed from 1990 to 2011 (accessed on 18/10/2012), only
4,431 (3%) are dedicated to biomarkers. The annual growth rate of biomarkers publications is consistently higher
than non-biomarkers publications, showing the growth in biomarkers research. From 20 years of systematic
review publications indexed in PubMed, we identified a bias in systematic reviews against the inclusion of
biomarker-based RCTs.
Conclusions: With the realisation of genome-based personalised medicine, biomarkers are becoming important for
clinical decision making. The bias against the inclusion of biomarkers in systematic reviews leads to medical
practitioners deprive of important information they require to address clinical questions. Sparse or weak evidence
and lack of genetic training for systematic reviewers may contribute to this trend.
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Evidence-Based Medicine (EBM) stipulates the use of
the best available external scientific evidence in clinical
decision making. Systematic Reviews (SRs) are con-
ducted through a well defined process [1], and published
as robust answers to clinical questions given the best
available evidence [2]. Randomized Controlled Trials
(RCTs) are trusted above all other primary evidence
types [1]. EBM is thus implemented by following clinical
practice guidelines (CPGs) or relying on SRs whenever
possible when making clinical decisions. Guideline and* Correspondence: m.choong@unsw.edu.au
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distribution, and reproduction in any mediumSR development is a slow and complex process or trans-
lating research that can take more than a year [3] to
complete. In this process it is critical to include all rele-
vant evidence [4]. It was previously claimed that as
much as 80% of all published reviews are not updated
and only 3% of systematic reviews published in peer-
reviewed journals had been updated within two years of
their publication [5]. Only a small proportion of relevant
trials are incorporated into systematic reviews [6].
The trend toward genome-based personalised medicine,
and the rapid advancement of sequencing and high-
throughput technologies, has dramatically reshaped disease
research. Genomic data can now be obtained expeditiously
and inexpensively. This has led to the use of a range of
analytical tools to assess biological parameters [7].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Publication type search based on publication
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are now standard practice in biomedical research. There
is an overwhelming interest in biomarker research
reflected in a large number of research grants awarded
and academic publications [8]. However, only a limited
number of biomarkers have been incorporated into clin-
ical guidelines [9], and the anticipation that biomarker
research will revolutionize medical practice has so far
not been realized. The ambiguity of the term “bio-
marker” has prompted the US National Institutes of
Health (NIH) to define the terminology. Biomarkers are
defined by the NIH Biomarkers Definitions Working
Group as “a characteristic that is objectively measured
and evaluated as an indicator of normal biological pro-
cesses, pathogenic processes, or pharmacologic responses
to a therapeutic intervention” [7]. Biomarkers are used as
tools in disease diagnostic, early detection, staging, prog-
nosis or prediction of treatment outcome. They can
guide individualized treatment and improve patient care
[9]. Biomarkers can provide the basis for design, improve
the safety and efficiency, and explain empirical results of
clinical trials [7].
The translation of biomarkers into clinical practice fol-
lows the regular translational pathways from discovery
to preclinical, clinical, and post-approval trials and im-
plementation. However, some translational crossroads
are unique to biomarkers [10,11]. In particular, the di-
versity and lengthy process of biomarker assay develop-
ment, and limited industry support were identified as
bottlenecks for translating biomarker research into clin-
ical practice. In this study, we examine the validation to
implementation phase (also called T2 [12]). As there are
cases of exaggeration in the effect sizes of many highly
cited biomarkers studies (which lead to overestimated
findings) [13], we measured the inclusion of RCTs of
biomarkers in SRs. We believe that prospective evalua-
tions of biomarkers in RCTs could provide more reliable
results about their effects and clinical utility.
We address the following questions:
1. How does the output frequency of publications that
include biomarkers compare to those that don’t?
2. Is the growth rate of publication of biomarkers RCTs
in line with the non-biomarkers publications?
3. To which extent biomarkers RCTs are being included
in SRs as compared to non-biomarkers RCTs?types of PubMed
Classification Publication type in PubMed
Systematic reviews (SR/MA) “Systematic Reviews” OR “Meta-Analysis”
Controlled Trial (RCT/CCT) “Randomized Controlled Trial” OR
“Controlled Clinical Trial”
Case Reports “Case Reports”
Non-systematic reviews “Review”Methods
Although there is no single database reliably showing
the true number of SRs or RCTs [6], we used PubMed
as the basis of our search. We searched for systematic
reviews, controlled trials, case reports and non-
systematic reviews by using the publication type inPubMed's Entrez search engine using the terms shown
in Table 1.
There are ambiguities in the naming and terminology
of the term “biomarker” within the literature [8]. As we
are interested in all biomarkers, we have included as
many terms with overlapping meaning of “biomarker” as
possible, such as biological marker/s, molecular marker/s,
genetic marker/s, DNA marker/s, cytogenetic marker/s,
proteomics marker/s and biochemical marker/s. We
repeated each search with (biomarker OR "biological mar-
ker" OR “biological markers” OR "molecular marker" OR
"molecular markers" OR "genetic marker" OR "genetic
markers" OR "DNA marker" OR "DNA markers" OR
"cytogenetic marker" OR "cytogenetic markers" OR "pro-
teomics marker" OR "proteomics markers" OR "bio-
chemical marker" OR "biochemical markers") helped
restrict the results to those biomarkers publications
only, and (all[sb] NOT (biomarker OR "biological
marker" OR “biological markers” OR "molecular marker"
OR "molecular markers" OR "genetic marker" OR
"genetic markers" OR "DNA marker" OR "DNA markers"
OR "cytogenetic marker" OR "cytogenetic markers"
OR "proteomics marker" OR "proteomics markers" OR
"biochemical marker" OR "biochemical markers")) for
non-biomarkers publications. “All publications” is the
summation of the above two complementary groups.
We limited our search to human subjects and to docu-
ments in English. All searches were done on the 18th of
October 2012.
In order to validate the search strategy, we randomly
chose 110 search results from each group (biomarkers and
non-biomarkers) of RCT/CCT (“Randomized Controlled
Trial” or “Controlled Clinical Trial”) and manually read
their abstracts and if needed their full text, to determine if
the trial is indeed about biomarkers or using biomarkers
as outcome measures.








where xi is the current year's total publications and
N=22 is the total number of years included in the study.
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trials publications in systematic reviews, we normalized
the systematic reviews samples by the number of pub-
lished clinical trials.
Results
The validation of search results on RCT/CCT yields an
accuracy of 0.82, with sensitivity of 0.76 and specificity
of 0.94.
While only a minority of trials has been included in
systematic reviews [6], this study found that the number of
trials involving biomarkers assessed in systematic reviews
is even smaller. With 147,774 systematic reviews indexed
in PubMed from 1990 to 2011 (accessed on 18/10/2012),
only 4,431 (3%) are dedicated to biomarkers.
Figure 1 shows a logarithmic representation of the cu-
mulative number of publications of clinical evidence
(SR/MT (“Systematic Reviews” or “Meta-Analysis”),
RCT/CCT, case reports and non-systematic reviews).
The growth of the publications of clinical evidence
appears to support the Prices Law of exponential growth
[14]. The total number of publications has increased tre-
mendously, from as low as 691 for SR/MA, 7402 for
RCT/CCT, 26,721 for case reports, and 25,261 for non-
systematic reviews in 1990 to 19,195, 23,488, 51,019,
74,411 in year 2011 respectively.
Figure 2 and Figure 3 show a logarithmic representa-
tion of the total number of publications of SR/MA,
RCT/CCT, case reports and non-systematic reviews
on biomarkers and non-biomarkers from 1990 to 2011.



















Figure 1 The cumulative number of all published systematic reviews,
The cumulative number of all published systematic reviews, controlled trial
1990 to 2011.case reports and non-systematic reviews increased for
biomarkers publications, so did the number of systematic
reviews. Figure 3 shows the same trend for non-
biomarker publications. The average annual growth rates
of biomarkers and non-biomarkers publications are
shown in Table 2. The annual growth rate of case reports
and non-systematic reviews are comparatively lower than
the SR/MA and RCT/CCT which are at the top two
of the hierarchy of clinical evidence. As evidenced by
annual growth rate where biomarkers publications are
consistently higher than non-biomarkers publications,
there is a growth in biomarkers research [15].
The ratio of systematic reviews over the published
clinical trials (ratio SR/RCT) of biomarkers and non-
biomarkers are shown in the solid line and dotted line of
Figure 4 respectively. The ratio SR/RCT represents how
many systematic reviews are published per clinical trials
in the same year. In other words, how likely a published
clinical trial is to be included in a SR. The ration
SR/RCT of both biomarkers and non-biomarkers publi-
cations is growing, reflecting the efforts of the review
community in assessing the published trials and produ-
cing systematic reviews at a growing rate. The ratio
SR/RCT of non-biomarkers publications is growing and
reached over 0.8, but the increased ratio SR/RCT on
biomarkers is comparatively lower and only reached 0.6
(if following the trend of overall publication, there are
about 20% to over 100% less systematic reviews on
biomarkers over the 22 years). The results show that
there are fewer systematic reviews published per







controlled trials, case reports and non-systematic reviews.
s, case reports and non-systematic reviews as identified in PubMed,



























Figure 2 The number of published systematic reviews, controlled trials, case reports and non-systematic reviews on biomarkers on a
logarithmic scale. The number of published systematic reviews, controlled trials, case reports and non-systematic reviews on biomarkers as
identified in PubMed, 1990 to 2011.
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versus SR/RCT of non-biomarkers publications. The
dotted line in Figure 5 represents the equal ratio of bio-
markers and non-biomarkers publications trend. The
biomarkers SR/RCT is consistently below that of non-
biomarker publications as shown in Figure 4 and
Figure 5. With the hypothesis that the likelihood of pub-
lished clinical trials is being included in systematic























Figure 3 The number of published systematic reviews, controlled tria
on logarithmic scale. The number of published systematic reviews, contro
as identified in PubMed, 1990 to 2011.same, it is clear that there is a preference towards non-
biomarkers publications.
From Figure 6, we can observe that the percentages
biomarkers publications in clinical trials and systematic
reviews are increasing. However, the proportion increase
in biomarker systematic reviews is comparatively lower
(the percentages in early 1990s might not be a good in-
dication as there are only a low number of published







ls, case reports and non-systematic reviews on non-biomarkers
lled trials, case reports and non-systematic reviews on non-biomarkers











SR/MA 4431 24.25 143343 17.67
RCT/CCT 12866 16.68 302940 5.64
Case Reports 22005 7.14 798765 3.09
Non-systematic reviews 47436 9.85 1014886 5.13
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search as the proportion of both biomarkers trials and
systematic reviews increases. The growth in the number
of biomarkers used in clinical trials and systematic
reviews has shown its importance.
Discussion
Biomedical research articles often include poor reporting
of statistical methods. Incomplete reporting of statistical
analysis limits or prevents the use of these studies in the
systematic reviews. This could explain why only a small
proportion of RCTs are included in systematic reviews.
Further study is needed to test if biomarkers RCTs are
more prone to bad statistical methods reporting than
other RCTs.
Our results show discrepancy between the rate of pub-
lications of biomarkers RCTs and biomarkers reviews.
Possible explanations for this include:
 The frequent proposals of new biomarkers and
assays which have complicated the translation and























Figure 4 Comparison of ratio of systematic reviews over controlled tria
of ratio of systematic reviews over controlled trials for biomarkers and non-bi Independent investigations in biomarkers show
contradicting results. A biomarker is ready for
clinical testing only when several retrospective tests
consistently confirm its performance [10]. As such,
weak and sparse evidence could not lead to any
conclusion.
 Systematic reviewers shy away from a domain in
which their training is lacking [16].
 Genetic disorders, where specific genetic variants
causally associated with common diseases, account
for only a fraction of cases [17], which result in
smaller cohorts for studies.
 RCTs, observational studies or cross-sectional
diagnostic studies are designed to answer
generalized clinical questions and ignore outliers.
Biomarker evidence might be too sensitive to
outliers [18] to provide low p-values.
 A few outliers might also cause small effects even in
large cohort studies [19] which would result in
exclusion from systematic reviews as they will
provide no clear difference from previous
summarized evidence.2002 2004 2006 2008 2010
io
r
ls for biomarkers and non-biomarkers publications. Comparison
omarkers publications, 1990 to 2011.
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Figure 5 Ratio of SR/RCT of biomarkers vs. ratio of SR/RCT of non-biomarkers publications. Ratio of SR/RCT of biomarkers vs. ratio of SR/
RCT of non-biomarkers publications, 1990 to 2011.
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significance which doesn't guarantee high
reproducibility [20,21].
As systematic reviews are the main source for guide-
line development, the lack of effort on systematically
reviewing studies in this area can explain why only a
limited number of molecular markers have been incor-
porated into clinical guidelines. There are still many























Figure 6 Comparison of percentages of clinical trials and systematic r
biomarkers over all clinical trials and percentage of systematic reviews on b
2011.systematic reviews and guidelines. This seems to be
stronger in biomarker evidence as we have shown.Conclusions
Biomarkers are becoming increasingly valuable in clin-
ical settings, whether to diagnose, prognosticate or to
guide treatment. It is important to fast track the research
and translation process. We identified the need for
systematic reviewers to include more biomarkers and0 2002 2004 2006 2008 2010
ntage
ear
eviews on biomarkers. Comparison of percentage of clinical trials of
iomarkers over all systematic reviews as identified in PubMed, 1990 to
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has not been done yet including lacking education of
systematic reviewers on molecular biology concepts
and the low predictive power of biomarkers. We pro-
pose that specific search technologies can support the
review process.
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